Research
Hormonal
Statins are the first-line pharmacologic therapy for lowering LDL-C and reducing cardiovascular events in patients with Type 2 Diabetes, regardless of baseline cholesterol levels.
If you have Type 2 Diabetes, talk to your doctor about starting a statin. It is the most effective way to lower your risk of heart attack and stroke, even if your cholesterol numbers look okay. Lifestyle changes are important, but statins provide the strongest protection.
StrongSupportsVERY_HIGH confidence
The HMG CoA reductase inhibitors, or 'statins,' are the most effective pharmacologic agents for reducing LDL-C concentrations and should be considered first-line therapy for this purpose, both in individuals with and without T2DM [48,63].
Why this rating
Supported by multiple large placebo-controlled clinical trials (CARDS, HPS, 4S, LIPID, etc.) and meta-analyses.
Source
Lipid and lipoprotein metabolism, hypolipidemic agents, and therapeutic goals
Gissette Reyes‐Soffer et al. · 2015
DOI 10.1002/9781118387658.ch17
book_chapter
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance is the primary driver of diabetic dyslipidemia, causing elevated triglycerides, low HDL-C, and small dense LDL particles through increased hepatic VLDL secretion and altered lipoprotein metabolism.Strong
- Lifestyle interventions (weight loss, diet, exercise) are key to treating diabetic dyslipidemia and can significantly reduce the incidence of Type 2 Diabetes in prediabetic individuals.Strong
- Targeting HDL-C and Triglycerides with non-statin drugs (niacin, fibrates) added to statins does not provide additional cardiovascular benefit compared to statin therapy alone in most cases.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →